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Abstract
Background:  Antipsychotic monotherapy is recognized as the treatment of choice for patients with
schizophrenia. Simultaneous treatment with multiple antipsychotics (polypharmacy) is suggested by some expert
consensus guidelines as the last resort after exhausting monotherapy alternatives. This study assessed the annual
rate and duration of antipsychotic monotherapy and its inverse, antipsychotic polypharmacy, among schizophrenia
patients initiated on commonly used atypical antipsychotic medications.
Methods: Data were drawn from a large prospective naturalistic study of patients treated for schizophrenia-
spectrum disorders, conducted 7/1997–9/2003. Analyses focused on patients (N = 796) who were initiated during
the study on olanzapine (N = 405), quetiapine (N = 115), or risperidone (N = 276). The percentage of patients
with monotherapy on the index antipsychotic over the 1-year post initiation, and the cumulative number of days
on monotherapy were calculated for all patients and for each of the 3 atypical antipsychotic treatment groups.
Analyses employed repeated measures generalized linear models and non-parametric bootstrap re-sampling,
controlling for patient characteristics.
Results: During the 1-year period, only a third (35.7%) of the patients were treated predominately with
monotherapy (>300 days). Most patients (57.7%) had at least one prolonged period of antipsychotic polypharmacy
(>60 consecutive days). Patients averaged 195.5 days on monotherapy, 155.7 days on polypharmacy, and 13.9 days
without antipsychotic therapy. Olanzapine-initiated patients were significantly more likely to be on monotherapy
with the initiating antipsychotic during the 1-year post initiation compared to risperidone (p = .043) or quetiapine
(p = .002). The number of monotherapy days was significantly greater for olanzapine than quetiapine (p < .001),
but not for olanzapine versus risperidone, or for risperidone versus quetiapine-initiated patients.
Conclusion:  Despite guidelines recommending the use of polypharmacy only as a last resort, the use of
antipsychotic polypharmacy for prolonged periods is very common during the treatment of schizophrenia patients
in usual care settings. In addition, in this non-randomized naturalistic observational study, the most commonly
used atypical antipsychotics significantly differed on the rate and duration of antipsychotic monotherapy. Reasons
for and the impact of the predominant use of polypharmacy will require further study.
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Background
Guidelines for treating patients with schizophrenia [1-5]
have long recognized antipsychotics as the core treatment
modality and have consistently recommended antipsy-
chotic monotherapy as the treatment of choice. Although
expert consensus guidelines do not advocate antipsy-
chotic polypharmacy, some [4] suggest antipsychotic
polypharmacy as the last resort after having exhausted
prior monotherapy alternatives. Only one of the consen-
sus guidelines [5] offers guidance on the duration of
antipsychotic polypharmacy, which is recommended
when switching from one antipsychotic to another (cross
titration or overlap and taper) and for not longer than 60
days.
Monotherapy is recognized as the preferred mode of treat-
ment because it allows clinicians to accurately evaluate
the patient's response to a new course of treatment [6].
Monotherapy permits documenting patient's response to
an adequate trial of each medication, helping to reduce
the complexity of the medication regimen, reducing the
risk of adverse events, and making it easier to assess and
manage future symptom exacerbations [7].
Despite consistent recommendations of antipsychotic
monotherapy, polypharmacy is widespread in the treat-
ment of schizophrenia [7-15]. The proliferation of antip-
sychotic polypharmacy is likely driven by increased
availability of pharmacologically diverse atypical antipsy-
chotics that augment an extensive armamentarium of typ-
ical antipsychotics. Generally, the concurrent use of more
than one antipsychotic, particularly of typical and atypical
agents, was reported to vary from 13% to 60%, depending
on the population studied, the year when the study has
been conducted, the study method, the type of treatment
site, and the duration of the study period [8,9,14,16-19].
The body of evidence supporting the benefits of antipsy-
chotic polypharmacy is limited [7,8,20,21] and is in con-
trast to the extensive and compelling body of evidence
supporting monotherapy with atypical antipsychotics
[6,7,9,11-13,22-24].
Antipsychotic polypharmacy was reported to increase the
risk of medication-related adverse events and of drug-drug
interactions, to increase the need for additional medica-
tions to treat emerging side-effects, to decrease adherence
with medication due to increased treatment complexity,
confounding clinicians' ability to discern helpful from
unhelpful medications, and to increase cost of care
[7,10,25]. A recent case-control study of psychiatric inpa-
tients demonstrated that short-term treatment with antip-
sychotic polytherapy was associated with major increases
in drug exposure, in adverse events, and in hospitalized
duration but with no apparent clinical benefit [16].
Antipsychotic polypharmacy appears to be used for vari-
ous reasons [7,11], with the one cited most often being
the wish to bolster medication effectiveness in treating
patients with refractory psychotic symptoms, mood symp-
toms, or behavioral problems [9]. It is, however, unclear
if antipsychotic polypharmacy is associated with specific
atypical antipsychotics more often than with others.
The body of research on differential monotherapy or poly-
pharmacy among atypical agents is sparse [8,26-30]. It is
unclear if risperidone and quetiapine-treated patients dif-
fer on monotherapy parameters. Most previous studies
reported higher monotherapy or lower polypharmacy
rates for olanzapine compared to risperidone
[18,19,28,29], and compared to quetiapine-treated
patients [25,27,30], whereas olanzapine and risperidone-
treated patients were not found to significantly differ on
polypharmacy rates in three studies [25-27]. The reasons
for the inconsistent findings are unclear but may stem
from methodological issues, including lack of complete
information about the use of depot antipsychotics, about
use of medications during psychiatric hospitalizations,
and inadequate control for potential selection effects,
which arise from clinicians' tendency to tailor treatment
regimens to patients' illness profiles and previous treat-
ment patterns.
This study expanded on prior research by using compre-
hensive medication data from a large prospective multi-
site naturalistic study of patients treated for schizophre-
nia-spectrum disorders in the United States to assess the
annual rate and duration of monotherapy, and its inverse,
antipsychotic polypharmacy. We also focused on patients
initiated on commonly used atypical antipsychotics –
olanzapine, quetiapine, or risperidone – and compared
their rates and duration of monotherapy during the year
following initiation on the antipsychotic medication.
Methods
Data source
This study used data of the U.S. Schizophrenia Care and
Assessment Program (US-SCAP), a large (N = 2327) non-
randomized, naturalistic, 3-year prospective multi-site
study conducted between 7/1997 and 9/2003. The goal of
US-SCAP was to understand the treatment of patients with
schizophrenia in usual care settings. Approximately 400
patients at each of the study's six regional sites were
enrolled. All participants were diagnosed with schizo-
phrenia, schizoaffective, or schizophreniform disorders
based on DSM-IV criteria, and were at least 18 years of age.
Patients were excluded if they were unable to provide
informed consent or had participated in a clinical drug
trial within 30 days prior to enrollment.BMC Psychiatry 2005, 5:26 http://www.biomedcentral.com/1471-244X/5/26
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In order to reduce selection bias, outpatients were ran-
domly selected from site medical information rosters of
active clients. Inpatients were sequential admissions. Of
3332 patients who met inclusion criteria, 765 (23.0%)
refused, and 240 (7.2%) were not enrolled for other rea-
sons. Most enrollees competed 1 year of follow-up
(78.1%), with fewer participants completing 2 years
(69.6%), and 3 years (65.2%). Of the 2327 enrollees,
21.2% were hospitalized at enrollment or during the 6
months prior to enrollment, and 36.2% were hospitalized
in the year prior to enrollment.
Participants were enrolled from six states (California,
Colorado, Connecticut, Florida, Maryland, and North
Carolina) and represented treatment in diverse systems of
care including community mental health centers, univer-
sity health care systems, the Department of Veterans
Affairs Health Services (VA), and community and state
hospitals. Institutional Review Board (IRB) approval was
received at each regional site and informed consent was
received from all participants.
At enrollment, almost all participants (94.7%) were
treated with at least one antipsychotic medication, includ-
ing oral typical (36.7%), oral atypical (58.1%), and depot
typical antipsychotics (19.6%). Medication changes dur-
ing the study period, including initiations and discontin-
uations, if any, were based on physicians' decisions as
they occur in usual care. Further details about US-SCAP
are available elsewhere [31,32].
The current study included data of US-SCAP participants
who were initiated on one of three commonly used atyp-
ical antipsychotics – olanzapine, quetiapine, or risperi-
done, in regular oral formulation. Participants were
defined as initiators if they were not prescribed the index
antipsychotic for at least 60 days prior to initiation, had at
least 2 months of treatment data available prior to initia-
tion of the index antipsychotic, and had at least 12
months of follow-up information in the study post initia-
tion. Inclusion of data for the 2 months prior to initiation
allowed for identification of variables on which the treat-
ment groups differed at the time of initiation. Further,
because this study aimed to assess use of antipsychotics
over a 1-year period, availability of a 12-month follow-up
period was necessary. Note that patients were not
excluded from the analysis if they stopped their antipsy-
chotic therapy – only if they discontinued or completed
the study within less than 12 months post initiation.
Some patients may have met inclusion criteria for being
an initiator of more than one medication throughout the
3-year period. Such patients were considered to be initia-
tors of the first antipsychotic medication they initiated in
the study.
Outcome measures
Medical records provided information about prescribed
psychiatric medications and were systematically
abstracted for the 6 months prior to enrollment and for
each 6-month interval thereafter. Patients were queried
about the use of medications and other mental health
resources outside those received at their regular treatment
site. When this occurred, systematic efforts were made to
abstract out-of-site medical records.
On a daily basis, monotherapy (polypharmacy) was
defined as the occurrence of one (more than one) ongoing
antipsychotic medication prescription. Predominant use
of monotherapy (polypharmacy) was defined as the use
of monotherapy (polypharmacy) for > 300 days out of the
year. Substantial monotherapy (polypharmacy) use was
defined as the use of monotherapy (polypharmacy) for >
60 to ≤  300 days out of the year. Consistent with expert
consensus guidelines [5], prolonged polypharmacy was
defined as a period of more than 60 consecutive days of
polypharmacy.
Two parameters of antipsychotic monotherapy were used
as the outcome measures for initiating treatment group
comparisons (olanzapine, quetiapine, or risperidone): (a)
the percentage of patients on antipsychotic monotherapy
with the index atypical antipsychotic over the 1-year post
initiation, and (b) the cumulative number of days of
antipsychotic monotherapy.
Participants were assessed with standard psychiatric meas-
ures at enrollment and at 12-month intervals thereafter.
These measures were not administered, however, at the
time of initiation or discontinuation of any medication.
Consequently, these variables were not used in this study.
Furthermore, the study did not assess reasons for medica-
tion initiation or discontinuation, thus eliminating the
ability to evaluate the reasons for any medication changes.
Statistical methods
Summary statistics were used to quantify monotherapy/
polypharmacy use at initiation on the medication and
across the 1-year period post initiation for all patients (N
= 796). This included summarizing the distribution of
durations on monotherapy/polypharmacy as well as clas-
sification of patients based on predominant, substantial
monotherapy/polypharmacy definitions and the pro-
longed use of polypharmacy.
To assess differences in the use of monotherapy between
the treatment groups, two statistical approaches were uti-
lized. First, treatment group differences in the percentage
of patients on monotherapy each day over the 1-year fol-
lowing initiation were assessed using a repeated measures
general linear model (GEE, Generalized EstimatingBMC Psychiatry 2005, 5:26 http://www.biomedcentral.com/1471-244X/5/26
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Equations) [33] with an exchangeable correlation matrix.
GEE models are widely used for analyzing longitudinal
binary data as they provide consistent parameter estimates
and account for the correlation of responses within
patients over time. The model consisted of terms for treat-
ment, time, treatment by time interaction, and a set of a
priori determined covariates discussed below. Second,
treatment group differences in the mean number of days
of monotherapy over the 1-year following initiation were
assessed. As the distribution of the number of days was
non-normal – with a high percentage of patients with zero
days, a non-parametric propensity score adjusted boot-
strap re-sampling approach was utilized [34].
In all treatment comparisons, differences were adjusted
for a set of available covariates selected a priori. These cov-
ariates were selected based on the expectations that they
may be associated with monotherapy use. Some clinical
variables that were collected at 1-year intervals in this
study were not used as covariates because they were not
collected at the point of initiation or discontinuation of
any medication. Thus, the covariates used for adjustment
in this study included available socio-demographic and
medication history variables: age, gender, ethnicity, ill-
ness duration, monotherapy status at initiation (yes/no),
investigational site, time, time by treatment interaction,
and the following variables based on the 2 months prior
to initiation of the index antipsychotic: any psychiatric
hospitalization, number of days of antipsychotic mono-
therapy, and any use of: typical antipsychotics, atypical
antipsychotics, antiparkinsonian agents, antidepressants,
anti-anxiety medications, sleep agents, mood stabilizers,
and typical antipsychotics in depot formulation.
No adjustment for multiple comparisons was performed
as we considered the repeated measures GEE model the
primary analysis and the monotherapy duration analysis
as a secondary analysis to assess the robustness of the pri-
mary results.
Results
Patient characteristics
Table 1 summarizes the socio-demographic characteristics
and medication history for the patient population. The
sample (N = 796) included patients who were initiated
during the study on olanzapine (N = 405), quetiapine (N
= 115), or risperidone (N = 276). While similar in many
aspects, the treatment groups differed on several charac-
teristics – most notably the percentage of patients on
antipsychotic polypharmacy at initiation, which was
highest among quetiapine-treated patients and lowest for
the risperidone treatment group. During the 2 months
prior to initiation on the index antipsychotic, a greater
percentage of quetiapine-treated patients were treated
with atypical antipsychotics and mood stabilizers; a
greater percentage of olanzapine-treated patients were
treated with typical antipsychotics in both oral and depot
formulations; risperidone patients had fewer antipsy-
chotic monotherapy days. Further, the quetiapine treat-
ment group had least males, the lowest illness duration,
and fewest patients with substance use disorders.
Medication dose
The dosing of each antipsychotic during the year post ini-
tiation, at initiation and at endpoint, and by mono-
therapy versus polypharmacy status at initiation is
presented in Table 2. Mean doses were higher at endpoint
than at initiation and were within the package insert
guidelines for the vast majority of the patients. In addi-
tion, the mean doses were higher for those on mono-
therapy than polypharmacy at initiation, but this was not
always found at endpoint.
Overall rates and duration of antipsychotic monotherapy/
polypharmacy
Approximately one-third (34%) of the 796 patients were
initiated on antipsychotic monotherapy with the index
antipsychotic. Conversely, most patients (66%) received
another antipsychotic, or polypharmacy, at the time of
initiation. Only 30% of the polypharmacy-initiated
patients were deemed to be in the process of medication
change because their polypharmacy ceased within 60 days
following initiation on the atypical agent.
The distribution of monotherapy and polypharmacy
treatment categories during the 1-year period (Figure 1)
indicates that about a third (35.7%) of the patients were
treated predominately with monotherapy (>300 days),
26.9% were treated predominately with polypharmacy
(>300 days), 30.2% had a mix of both substantial
monotherapy and polypharmacy treatment periods (61–
300 days of each), and 0.6% were not treated with any
antipsychotic for more than 300 days. A small proportion
of the patients (6.6%) had periods without antipsychotic
medications along with substantial treatment periods
with either monotherapy or polypharmacy (61–300
days).
Overall, patients averaged 195.5 days on monotherapy
(54% of the year), 155.7 days on polypharmacy (43% of
the year), and 13.9 days without antipsychotic therapy
(3% of the year). The distribution of the average number
of polypharmacy days for each patient over the 1-year
period (Figure 2) indicates that 40.6% had polypharmacy
for less than 60 days. In fact, most patients (57.7%) had
at least one prolonged period of antipsychotic polyphar-
macy (longer than 60 consecutive days).BMC Psychiatry 2005, 5:26 http://www.biomedcentral.com/1471-244X/5/26
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Specific rates and duration of monotherapy/
polypharmacy
A significantly greater percentage of olanzapine-treated
patients were on antipsychotic monotherapy during the 1-
year period compared to risperidone and to quetiapine.
Olanzapine-treated patients were 2.08 times more likely
to be on monotherapy than quetiapine (Odds Ratio (OR)
= 2.08, 95% Confidence Interval (CI), 1.30–3.31, p =
.002), and 1.36 times more likely to be on monotherapy
than risperidone (OR = 1.36, 95%CI, 1.01–1.84, p =
Table 1: Baseline characteristics of patients initiated on olanzapine, risperidone, and quetiapine
Variable Olanzapine N = 405 Quetiapine N = 115 Risperidone N = 276
Age, mean (S.D.) 41.8 (10.5) 39.6 (10.9) 40.4 (12.1)
Illness duration (yrs), mean (S.D.) * a,b 22.1 (11.3) 18.5 (11.2) 19.9 (12.4)
Male gender* b 61.7% 47.8% 54.7%
Ethnicity
White 46.7% 53.9% 45.3%
Black 41.2% 33.9% 36.6%
Other 12.1% 12.2% 18.1%
Schizoaffective disorder 32.6% 40.0% 33.3%
Substance-use disorder* b,c 30.9% 19.3% 29.4%
No insurance 6.9% 8.9% 9.2%
Polypharmacy at initiation * a,c 67.2% 76.5% 59.8%
Prior treatment pattern †
Prior Antipsychotic monotherapy days, mean (S.D.)* a 42.4 (26.0) 39.2 (27.7) 36.8 (28.0)
Prior psychiatric hospitalization* a 21.0% 21.7% 29.4%
Prior atypical antipsychotic* b,c 23.5% 69.6% 28.6%
Prior typical oral antipsychotic* b,c 63.5% 39.1% 58.7%
Prior typical depot antipsychotic* a,b 23.2% 13.9% 15.9%
Prior antidepressants 35.6% 45.2% 40.9%
Prior anti-anxiety agents 10.4% 14.8% 12.0%
Prior antiparkinsonians agents 46.9% 36.5% 47.5%
Prior mood stabilizers* a,c 30.1% 39.1% 23.2%
Prior sleep agents 0.7% 3.5% 2.2%
* Significant groups difference at p < 0.05
asignificant pairwise comparisons olanzapine vs. risperidone
b significant pairwise comparisons olanzapine vs. quetiapine
c significant pairwise comparisons risperidone vs. quetiapine
† Treatment pattern during the 2 months prior to initiation on the index drug
Table 2: Daily Dose (mg/day) of Index Atypical Antipsychotic: During the 1-Year Post Initiation, at Initiation, and at Endpoint
Group/Time Mean (SD) Median Min/Max Mean Mono/Poly*
Olanzapine
1-Year 13.9 (7.4) 10.0 2.5/40 15.1/13.5
Initiation 10.0 (6.1) 10.0 2.5 / 40 10.7 / 9.5
Endpoint 14.2 (8.4) 10.0 2.5 / 50 13.9 / 14.5
Quetiapine
1-Year 330 (214) 295 25/850 305/334
Initiation 164.2 (151) 100 12.5 / 800 223 / 138
Endpoint 341 (277) 300 25 / 1300 369 / 330
Risperidone
1-Year 4.2 (2.3) 3.9 0.28/12.9 4.7/3.9
Initiation 2.7 (2.0) 2.0 0.25 / 12 3.2 / 2.4
Endpoint 4.3 (2.7) 4.0 0.25 / 16 4.5 / 4.1
* Mean Mono/Poly indicates the mean dose (mg/day) for patients while on antipsychotic monotherapy, and while on antipsychotic polypharmacyBMC Psychiatry 2005, 5:26 http://www.biomedcentral.com/1471-244X/5/26
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.043). Differences between risperidone and quetiapine
initiators showed a trend toward significance (OR = 1.53,
95% CI, 0.94–2.47, p = .085).
The percentages of patients on antipsychotic mono-
therapy during every week in the 1-year following initia-
tion for each treatment group are provided in Figure 3.
Due to the strong influence of monotherapy status at ini-
tiation on later monotherapy status, and the treatment
differences in monotherapy status at initiation, results are
also shown stratified by monotherapy status at initiation
in Figure 4.
The observed mean number of monotherapy days on the
initiating antipsychotic for olanzapine, quetiapine, and
risperidone are presented in Table 3 for patients initiating
on monotherapy and for patients initiating on polyphar-
macy. For monotherapy or polypharmacy initiators,
patients on olanzapine had a greater number of days of
monotherapy on the initiating medication while quetiap-
ine initiators had the fewest. Using a propensity score
bootstrap analysis, pair-wise comparisons found a signif-
icantly longer duration on monotherapy for olanzapine
compared to quetiapine (p < .001) and a trend toward
longer duration for risperidone initiators as compared to
quetiapine (p = .052). The difference between olanzapine
and risperidone was not statistically significant.
Discussion
In this large prospective naturalistic study of patients with
schizophrenia, antipsychotic polypharmacy was found to
be highly prevalent and to be of prolonged duration.
Overall, most patients (57.7%) had at least one period of
antipsychotic polypharmacy longer than 60 consecutive
days, and only a third (35.7%) of the patients were treated
predominately with monotherapy. More specifically, two
thirds (66%) of the patients were treated with another
antipsychotic at the time of initiation on the atypical
agent, a practice that could have signaled a medication
change process. However, most of these patients contin-
ued on antipsychotic polypharmacy for a substantial
duration and only a small proportion of those patients
(30%) were deemed to have gone through medication
changes as polypharmacy ceased within the first 60 days
after medication initiation. Findings suggest that for the
majority of patients, polypharmacy is a prolonged and
deliberate treatment choice rather than an interim, brief,
or unintentional practice.
A third (34%) of the patients were not receiving another
antipsychotic at the time of initiation on the studied atyp-
ical medications (olanzapine, quetiapine, and risperi-
done). These monotherapy-initiated patients continued
on monotherapy for only about a third of the year post
initiation, and at the end of that year, more than 50% of
them were no longer receiving monotherapy with the ini-
tiating antipsychotic. Further attesting to the pervasive
practice of antipsychotic polypharmacy is the finding that
over 40% of all patients had no days of monotherapy with
the initiating atypical antipsychotics during the 1-year
treatment period. On the average, patients were treated
with monotherapy for 54% of the year, with polyphar-
macy for 43% of the year, and without antipsychotic ther-
apy for 3% of the year.
While polypharmacy was found to be prevalent in this
patient population, the question of generalizability
remains. However, a goal in designing the US-SCAP study
was to generate a sample of patients representative of
those treated in usual care. Participants in this large pro-
spective naturalistic study were treated for schizophrenia
at large public health care delivery systems in the United
States, and were enrolled from multiple sites across six
states. The patients were randomly identified from active
client rosters at each site and only then approached about
Percent of patients in each monotherapy/polypharmacy  treatment category Figure 1
Percent of patients in each monotherapy/polypharmacy 
treatment category. Abbreviations: Mono, monotherapy; 
Poly, polytherapy; No AP, no antipsychotic treatment. Defi-
nitions: Monotherapy: Predominant antipsychotic mono-
therapy (> 300 days); Polypharmacy: Predominant 
antipsychotic polypharmacy (> 300 days); Mix: Mono/Poly: 
Substantial periods of monotherapy (61 to 300 days) and 
substantial periods of polypharmacy (61 to 300 days), but no 
substantial periods of no antipsychotic treatment (< 60 days); 
No Antipsychotic: Patients predominately without pre-
scribed antipsychotics (> 300 days); Mix: No AP/Mono: 
Patients predominately without prescribed antipsychotics (> 
300 days) and substantial periods of monotherapy (61 to 300 
days); Mix: No AP/Poly: Patients predominately without pre-
scribed antipsychotics (> 300 days) and substantial periods of 
polypharmacy (61 to 300 days).BMC Psychiatry 2005, 5:26 http://www.biomedcentral.com/1471-244X/5/26
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enrollment in the study. In addition, there were few exclu-
sion criteria that would restrict the patient population.
This study provided a 1-year longitudinal perspective on
the rate and duration of polypharmacy following initia-
tion on the index antipsychotic whereas most previous
studies assessed polypharmacy during shorter time peri-
ods, such as a 2-month window [15], or during inpatient
hospitalization [16,19,25,26]. Generally, the larger is the
studied time window, the higher is the likelihood of find-
ing polypharmacy. Another major difference is the age of
the data because polypharmacy has increased over the
years. Studies using data from the earlier years after the
introduction of the atypical antipsychotics [10,14] tend to
report lower prevalence rates of antipsychotic polyphar-
macy, whereas studies using more recent data reported
higher polypharmacy rates [8,15]. The complexity
involved in comparing findings across studies is further
compounded by variations in the definition of polyphar-
macy. Although most studies defined polypharmacy as
any time with more than one antipsychotic [15], others
have set specific time requirements, such as at least 14
days of concurrent antipsychotic use [8]. Other differences
in study methods can generate different results. While the
current study followed patients after their initiation on
certain antipsychotic medications, other studies used a
cross sectional method, assessing the prevalence of
polypharmacy at a given time window, without using
time of initiation on the studied antipsychotic medica-
tions as the reference point. While cross sectional designs
provide important information about prevailing practices
at a given time window, the cross sectional method is not
well suited for comparisons between antipsychotic treat-
ment groups. When the date of initiation on the antipsy-
chotic is not used as a starting point, treatment group
differences may be obscured by differential duration on
the medication prior to the studied time window, data
that are not included in cross sectional designs.
This study also found significant differences in mono-
therapy and polypharmacy between the most commonly
prescribed atypical antipsychotic medications. Patients
initiated on olanzapine were significantly more likely to
be on monotherapy compared to quetiapine (rate and
duration) or risperidone-initiated patients (rate only) dur-
ing the 1-year post treatment initiation. The current find-
ings appear consistent with several previous studies in
which olanzapine-treated patients were found to have sig-
nificantly higher rate of monotherapy compared to risp-
eridone [18,19,28,29], and compared to quetiapine-
treated patients [25,27,30], with the quetiapine treatment
group being the least likely to be treated monotherapy
Percent of patients with antipsychotic polypharmacy during the 1-year period by duration category Figure 2
Percent of patients with antipsychotic polypharmacy during the 1-year period by duration category.BMC Psychiatry 2005, 5:26 http://www.biomedcentral.com/1471-244X/5/26
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[8,27]. Findings are particularly congruent with those
reported in a study of medication patterns in the Michigan
Medicaid database [28], in which the proportion of schiz-
ophrenia patients treated with olanzapine monotherapy
remained relatively steady over the first 3 months of treat-
ment while the proportion of patients receiving risperi-
done monotherapy decreased over time.
The present study helps demonstrate the dynamic and
complex nature of medication management of patients
with schizophrenia in usual clinical practice [14]. In
addition to providing new information on the rate of
monotherapy during treatment with various atypical
agents, this study further contributes to the literature by
providing a longitudinal perspective on the duration of
monotherapy/polypharmacy following treatment initia-
tion. The strengths of this study appear to lie in its large
representative and diverse sample, the ability to provide
comparative data on a number of commonly used atypi-
cal antipsychotics, the availability of comprehensive med-
ication information about use of antipsychotics in depot
formulation and about antipsychotics used during hospi-
talizations (types of data often absent in claims data-
bases), and notably, the ability to generalize the findings
to patients treated at large public systems of health care
across the United States.
This study also has its limitations. First is the use of natu-
ralistic observational data to compare antipsychotic
treatment groups, because observed group differences in
rates or duration of monotherapy could result from pre-
existing differences between the treatment groups rather
than differences in medication choice. Physicians tend to
select treatments for different types of patients and illness
profiles, a practice that may lead to lack of comparability
between the treatment groups at initiation. Analyses that
Percent of patients on monotherapy during the 1-year following initiation on the atypical antipsychotic medication Figure 3
Percent of patients on monotherapy during the 1-year following initiation on the atypical antipsychotic medication. Using a GEE 
(generalized estimating equations) repeated measures binary data model, pair-wise comparisons found a significantly higher 
rate of monotherapy for olanzapine compared to quetiapine (p = .002) and risperidone (p = .043). The difference between ris-
peridone and quetiapine approached statistical significance (p = .085).BMC Psychiatry 2005, 5:26 http://www.biomedcentral.com/1471-244X/5/26
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do not appropriately control for such differences can be
biased, and one can never be certain that all important
group differences have been controlled for statistically.
Indeed, in this study differences were observed between
groups at initiation. Although differences in several avail-
able pre-existing patient and treatment characteristics
were controlled for in the analysis, it is possible that other
pre-existing group differences were present. For instance,
the design of this study did not include assessment of
symptom severity or substance use at the time of initiation
on the index antipsychotic. Thus, differences in symptom
severity or substance use at initiation could not be con-
trolled for.
Another study limitation is lack of information about rea-
sons for initiating antipsychotic medication changes or
the specific treatment indications. This type of informa-
tion was not assessed in US-SCAP but could be valuable
Percent of patients on monotherapy after initiation on antipsychotic polypharmacy or antipsychotic monotherapy Figure 4
Percent of patients on monotherapy after initiation on antipsychotic polypharmacy or antipsychotic monotherapy. Abbrevia-
tions: OLZ, olanzapine; Poly, polypharmacy at initiation; QUE, quetiapine; RIS, risperidone; Mono, monotherapy at initiation
Table 3: Number of monotherapy days on the initiating antipsychotic during the 1-year post initiation
Status at Initiation
Treatment Monotherapy Polypharmacy Overall Mean
N Mean (SD) N Mean (SD) (SD)
Olanzapine 133 252.1 (132.8) 272 90.2 (126.8) 143.4 (149.5)
Quetiapine 27 159.8 (142.4) 88 53.6 (102.1) 78.5 (120.9)
Risperidone 111 230.6 (143.8) 165 78.0 (121.2) 139.3 (150.5)
Abbreviation: SD, standard deviation.BMC Psychiatry 2005, 5:26 http://www.biomedcentral.com/1471-244X/5/26
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in discerning whether there is a link between treatment
effectiveness and antipsychotic monotherapy (or polyp-
harmacy). Treatment indication is also important because
some antipsychotics, particularly quetiapine in low doses,
may have been used to treat insomnia rather than core
symptoms of schizophrenia. Although some have specu-
lated that higher doses of quetiapine produce better out-
come, the available data [35] do not support this. Davis
and Chen [35] observed, however, "the sponsor of
quetiapine has 2 studies of dose response, one nearing
completion, and the other just beginning, so more
information will be available in the future". They also
noted "the fact that individuals do clinically improve at
higher doses in open studies does not prove that the
higher dose was responsible, as such improvement might
reflect the passage of time, augmenting drugs, or other
confounding factors."
Further, this study did not control for potential "sponsor-
ship" bias that could have influenced clinicians' prescrip-
tion rates and duration of monotherapy in favor of the
sponsor's antipsychotic medication (in this case,
olanzapine). Although we cannot completely rule out this
possibility, sponsor bias is unlikely to have played a role
in this study because the current findings are highly con-
sistent with findings of other studies conducted by inde-
pendent researchers who used non-industry-sponsored
data such as Medicaid claims database [18,19,28,29].
Additional support for the validity of our findings and
their freedom from sponsorship bias comes from a recent
double-blind randomized study conducted by the spon-
sors of risperidone [35], comparing risperidone and
quetiapine on the rate of antipsychotic polypharmacy.
That short term trial found the relative risk (quetiapine vs.
risperidone) of using antipsychotic polypharmacy to be
higher for quetiapine compared to risperidone (odds ratio
1.90, 95% CI, 1.29–2.80, p = 0.001), a finding similar to
that in our observational study, in which the odds ratio
for antipsychotic polypharmacy of quetiapine vs. risperi-
done was 1.53 (95% CI 0.94–2.47, p = 0.085).
This study also did not present information about con-
comitant use of psychotropic medications other than
antipsychotics, thus providing a partial understanding of
the full range of psychotropic polypharmacy that takes
place in usual practice. This is a complex phenomenone
that will benefit from a separate and detailed study. We,
however, cognizant of the potential role of prior concom-
itant psychotropic medications and used five types of psy-
chotropics (antidepressants, anti-anxiety,
antiparkinsonian, mood stabilizers, and sleep agents) in
the analyses. Because prior use of concomitant psycho-
tropics is highly correlated with continued use of these
concomitant medications post initiation of the new antip-
sychotic regimen, we opted to include patients' prior con-
comitant medication as covariates in the analyses. The
correlations between concomitant psychotropic medica-
tion use prior to initiation on the index drug and its
concomitant use post initiation on the antipsychotic were
consistently high, ranging from .65 to .81 (r = .81 for anti-
depressants, r = .80 for anti-anxiety agents, r = .73 for
antiparkinsonians, r = .81 for mood stabilizers, and r = .65
for sleep agents). These correlations suggest that the bigger
factor in the use of concomitant psychotropic medications
post antipsychotic initiation is likely patients' prior medi-
cation history and not the antipsychotic monotherapy/
polypharmacy status. Generally, the mean daily total
number of concomitant psychotropic medications was
higher for patients on antipsychotic polypharmacy (1.56)
than for patients on antipsychotic monotherapy (1.24).
Lastly, this study did not address the potential impact of
polypharmacy on the total cost of antipsychotic treat-
ment, or on patients' clinical outcomes, an area of investi-
gation that will require further study.
Conclusion
This large prospective study of treatment in usual care set-
tings demonstrated that antipsychotic medication man-
agement of schizophrenia patients is a complex process
characterized by prevalent and prolonged polypharmacy.
Current findings also highlight differences between the
most commonly used atypical antipsychotics on the rate
and duration of antipsychotic monotherapy, and its
inverse, antipsychotic polypharmacy. Future research is
needed to clarify the reasons for the observed treatment
group differences, and to investigate the potential impact
of antipsychotic polypharmacy on the costs of treatment
and other important treatment outcomes in the long-term
medication management of patients with schizophrenia.
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